Perjeta FDA Approval History
FDA Approved: Yes (First approved June 8, 2012)
Brand name: Perjeta
Generic name: pertuzumab
Dosage form: Injection
Treatment for: Breast Cancer
Perjeta (pertuzumab) is a humanized monoclonal antibody indicated for the treatment of HER2-positive breast cancer.Perjeta used in combination with Herceptin, another targeted therapy medicine, and Taxotere, a type of chemotherapy, to treat HER2-positive, metastatic breast cancer that hasn’t been treated with either Herceptin or chemotherapy yet. Perjeta was called Omnitarg in earlier studies.
Development Timeline for Perjeta
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.